Overall, there was a “modest” decline in use of embolic protection in the year after the PROTECTED TAVR results were released ...
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
Payment will be provided when TTVR is delivered for an FDA-approved indication in the context of a CMS-approved study.
Out-of-hospital mortality before 30 days was 1.2%, with roughly two-thirds of these patients dying from cardiovascular causes.
With about 7% of CVD in the country attributable to high temperatures, experts say tools to adapt are urgently needed.
Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.
In this “data-scarce zone,” the paper offers a road map for the first 24 hours and tips for transfer, teams, and more.
A risk-assessment tool incorporating NT-proBNP and high-sensitivity troponin performs better than clinical scores for ...
Clinicians should be asking patients about cannabis use, particularly if there are cardiovascular concerns, say researchers.
Patients can now easily buy these tests, but cardiologists must consider their quality when using the information to guide ...
Early data in mice and human tissue indicate that using drugs or gene therapy could allow for cardiac healing in ischemic HF.
The US data also point to lower costs and shorter stays at these expert centers, an argument for regionalized care akin to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results